Deciphering the circadian signature in acute myeloid leukemia: NPAS2 downregulation as a master predictive feature [0.03%]
急性髓系白血病的昼夜节律特征解析：NPAS2低表达作为主导预测标志
Leidivan Sousa da Cunha,Guilherme Passos de Morais,Caio Bezerra Machado et al.
Leidivan Sousa da Cunha et al.
Purpose: Considering the role of circadian clock genes in leukemogenesis through the regulation of cell cycle progression and genomic stability, this study aimed to evaluate the expression of NPAS2, CIPC, BMAL1, and CLOCK...
Myeloid-lineage blasts with histiocytoid differentiation in TP53 mutated acute myeloid leukemia: a deceptive morphologic overlap with mature malignant histiocytic neoplasms [0.03%]
TP53突变急性髓系白血病中具有组织细胞样分化的粒-单核幼细胞与成熟恶性组织细胞肿瘤的形态重叠
Neha Seth,Aishwarya Ravindran
Neha Seth
Here, we report a case of TP53-mutated acute myeloid leukemia (AML) with monocytic differentiation that showed striking histiocytoid morphologic transformation following induction chemotherapy. Post-treatment blasts demonstrated significant...
2026 Korean expert recommendations for the use of thrombopoietin receptor agonists in severe aplastic anemia [0.03%]
2026年韩国专家关于血小板生成素受体激动剂治疗重症再生障碍性贫血的推荐意见
Silvia Park,Jun Ho Jang,Ik-Chan Song et al.
Silvia Park et al.
The treatment landscape for severe aplastic anemia (SAA) has undergone a significant paradigm shift with the integration of thrombopoietin receptor agonists (TPO-RAs) into standard immunosuppressive therapy (IST). However, clinical practice...
Clinical heterogeneity of primary cutaneous γδ T-cell lymphoma: a 20-year single-institution experience [0.03%]
原发性皮肤γδ T细胞淋巴瘤的临床异质性：单中心20年经验
Miran Han,Sang Eun Yoon,Junhun Cho et al.
Miran Han et al.
Purpose: Primary cutaneous γδ T-cell lymphoma (PCGDTCL) is a rare cutaneous T-cell lymphoma defined by γδ T-cell receptor expression and a cytotoxic phenotype. It has historically been considered highly aggressive, wi...
Response-adapted lenalidomide-dexamethasone (LenDex) intensification after CyBorD induction for transplant-eligible multiple myeloma: the PIANO study [0.03%]
移植合格的多发性骨髓瘤患者在硼替佐米诱导治疗后根据个体反应调整来那度胺-地塞米松强化治疗：PIANO研究
Daisuke Minakata,Go Yamamoto,Shinichi Kako et al.
Daisuke Minakata et al.
Purpose: Combination therapy with novel agents is the standard initial treatment for transplant-eligible patients with newly diagnosed multiple myeloma. However, the benefit of additional induction therapy for insufficien...
Asciminib as first-line therapy in chronic myeloid leukemia: a systematic review [0.03%]
艾斯西明用于慢性粒细胞白血病一线治疗的系统评价研究
Jae Joon Han,Jeong-Ok Lee,Kyoung Ha Kim et al.
Jae Joon Han et al.
Purpose: Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by the BCR::ABL1 fusion oncogene. Asciminib, a first-in-class STAMP (Specifically Targeting the ABL Myristoyl Pocket) inhibitor, repre...
Recent advances in the treatment of FLT3-mutated acute myeloid leukemia [0.03%]
治疗FLT3突变急性髓系白血病的最新进展
Jeong Suk Koh,Ik-Chan Song
Jeong Suk Koh
FMS-like tyrosine kinase 3 (FLT3) mutations are among the most common driver alterations in acute myeloid leukemia (AML), occurring in approximately 25-30% of patients, and have historically been associated with high relapse rates and poor ...
Primary breast follicular lymphoma without a BCL2 rearrangement: insights into extranodal lymphoma biology [0.03%]
没有BCL2重排的主要乳腺滤泡性淋巴瘤：关于结外淋巴瘤生物学的启示
Neha Seth,Anam Khan,Elaine Zhong et al.
Neha Seth et al.
Background: Primary breast lymphoma is a rare malignancy that accounts for less than 1% of non-Hodgkin lymphomas. Diffuse large B-cell lymphoma is the most common subtype, whereas follicular lymphoma (FL) accounts for onl...
Nuanced treatment decision in newly diagnosed multiple myeloma patients aged 65-75 years: a real-world study [0.03%]
初治65至75岁多发性骨髓瘤患者的治疗决策分析：一项真实世界研究
Naryllae Lee,Seoyeon Kim,Yugyeong Lee et al.
Naryllae Lee et al.
Purpose: The optimal treatment strategy for patients aged 65-75 years with multiple myeloma (MM) remains undefined, as most clinical trials involving transplant-eligible patients have excluded this subgroup. We investigat...
Shailesh Simkhada,Utsav Joshi,Prajwal Dhakal
Shailesh Simkhada
Acute myeloid leukemia (AML) is a molecularly diverse hematologic malignancy, with clinical outcomes driven by patient fitness, disease biology, and the depth of remission. Over the past decade, the increasing use of molecular studies has e...